Filing Flows › Artivion (AORT) › Guidance & outlook
Artivion (AORT) guidance and outlook
Artivion (AORT) narrowed its guidance on Nov 5, 2026: Revenue $484M–$492M for FY2026; Revenue +8% to +10% for FY2026; EBITDA $93.0M–$98.0M for FY2026. Artivion's 10-Q filed Nov 6, 2026 makes 5 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $484M–$492M | reaffirmed |
| Revenue | FY2026 | +8% to +10% | reaffirmed |
| EBITDA | FY2026 | $93.0M–$98.0M | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- Additionally, our sales to many distributors around the world are denominated in US Dollars, and although these sales are not directly impacted by currency exchange rates, we believe that some of our distributors may delay or reduce purchases of products in US Dollars depending on the relative price of these goods in their local currencies.
- As discussed in Part I, Item 1, Note 2 of the “Notes to Condensed Consolidated Financial Statements,” we expect to conclude our PerClot manufacturing activities under the Transitional Manufacturing and Supply Agreement with Baxter by the end of 2026.
- Our future cash requirements are expected to include interest payments under our credit facilities, expenditures for clinical trials, research and development expenditures, general working capital needs, capital expenditures, other corporate purposes, and may include cash to fund other business development activities including obligations pursuant to the acquisition of Ascyrus and Endospan.
- There can be no assurance that we will be able to obtain any additional debt or equity financing at the time needed or that such financing will be available on terms that are favorable or acceptable to us.
- As of September 30, 2026 our total principal indebtedness was $370.0 million, and our anticipated interest payments related to the Term Loan Facility, Revolving Credit Facility, and New Delayed Draw Term Loan Facility were $149.6 million.
Artivion's latest quarter
Artivion, Q3 2026: revenue $124M (+9% year over year), operating margin 2.4%, net loss $7.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Questions
Did Artivion raise or lower its guidance?
Artivion (AORT) narrowed its guidance on Nov 5, 2026: Revenue $484M–$492M for FY2026; Revenue +8% to +10% for FY2026; EBITDA $93.0M–$98.0M for FY2026.
What does Artivion expect?
Additionally, our sales to many distributors around the world are denominated in US Dollars, and although these sales are not directly impacted by currency exchange rates, we believe that some of our distributors may delay or reduce purchases of products in US Dollars depending on the relative price of these goods in their local currencies. As discussed in Part I, Item 1, Note 2 of the “Notes to Condensed Consolidated Financial Statements,” we expect to conclude our PerClot manufacturing activities under the Transitional Manufacturing and Supply Agreement with Baxter by the end of 2026. Our fu
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.